BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35505351)

  • 1. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.
    Ohno M; Miyakita Y; Takahashi M; Yanagisawa S; Tamura Y; Kawauchi D; Kikuchi M; Igaki H; Yoshida A; Satomi K; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2022 May; 17(1):85. PubMed ID: 35505351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
    Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
    Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifocal high-grade glioma radiotherapy safety and efficacy.
    Fleischmann DF; Schön R; Corradini S; Bodensohn R; Hadi I; Hofmaier J; Forbrig R; Thon N; Dorostkar M; Belka C; Niyazi M
    Radiat Oncol; 2021 Aug; 16(1):165. PubMed ID: 34454558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Yoon BH; Park JS; Kang S; Kwon NJ; Lee KS; Kim CY; Choe G
    Br J Neurosurg; 2023 Oct; 37(5):1233-1236. PubMed ID: 33095064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
    Kanamori M; Kikuchi A; Watanabe M; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Kumabe T; Kure S; Tominaga T
    J Neurosurg; 2014 Jun; 120(6):1288-97. PubMed ID: 24745708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
    Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
    Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TERT mutation for treatment prognosis in patients with IDH-negative anaplastic astrocytoma.
    Belyaev AY; Kobyakov GL; Shmakov PN; Telysheva EN; Strunina YV; Usachev DY
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(5):21-27. PubMed ID: 36252190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
    Juratli TA; Cahill DP; McCutcheon IE
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):603-6. PubMed ID: 25980633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
    Singh A; Gurav M; Dhanavade S; Shetty O; Epari S
    Neuropathology; 2017 Dec; 37(6):582-585. PubMed ID: 28782849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
    Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
    Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
    Mascelli S; Raso A; Biassoni R; Severino M; Sak K; Joost K; Milanaccio C; Barra S; Grillo-Ruggieri F; Vanni I; Consales A; Cama A; Capra V; Nozza P; Garrè ML
    J Neurooncol; 2012 Sep; 109(3):477-84. PubMed ID: 22821382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
    J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.